Lauren A V Orenstein1, Tien V Nguyen2, Giovanni Damiani3, Christopher Sayed4, Gregor B E Jemec5, Iltefat Hamzavi6. 1. Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA, Lauren.Orenstein@emory.edu. 2. Bellevue Dermatology Clinic and Research Center, Bellevue, Washington, USA. 3. Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Unità Operativa di Dermatologia, IRCCS Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy. 4. Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. 5. Department of Dermatology, Zealand University Hospital Roskilde, Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark. 6. Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic painful skin disease that severely impairs patients' quality of life. While high-quality trials of HS therapies remain limited, medical knowledge of best treatment practices is rapidly evolving, leading to the recent publication of multiple international treatment guidelines for HS. SUMMARY: This review compares international HS treatment guidelines, describes evidence for effectiveness of common and emerging HS therapies, and provides guidance for integrating evidence-based HS care into practice. Although over 50 medical and procedural treatments are mentioned across international HS guidelines, only adalimumab and infliximab have grade B/weak recommendation or higher across all major guidelines. This review describes the appropriate patient selection and effectiveness of the most commonly used medical and procedural treatments for HS. It also includes recommendations for counseling, dosing, and duration of medical therapies as well as procedure videos for the practicing dermatologist.
BACKGROUND:Hidradenitis suppurativa (HS) is a chronic painful skin disease that severely impairs patients' quality of life. While high-quality trials of HS therapies remain limited, medical knowledge of best treatment practices is rapidly evolving, leading to the recent publication of multiple international treatment guidelines for HS. SUMMARY: This review compares international HS treatment guidelines, describes evidence for effectiveness of common and emerging HS therapies, and provides guidance for integrating evidence-based HS care into practice. Although over 50 medical and procedural treatments are mentioned across international HS guidelines, only adalimumab and infliximab have grade B/weak recommendation or higher across all major guidelines. This review describes the appropriate patient selection and effectiveness of the most commonly used medical and procedural treatments for HS. It also includes recommendations for counseling, dosing, and duration of medical therapies as well as procedure videos for the practicing dermatologist.
Authors: Anna Schuch; Tatjana Fischer; Alexander Boehner; Tilo Biedermann; Thomas Volz Journal: Acta Derm Venereol Date: 2018-01-12 Impact factor: 4.437
Authors: Michael V DeFazio; James M Economides; Kathryn S King; Kevin D Han; Victoria K Shanmugam; Christopher E Attinger; Karen K Evans Journal: Ann Plast Surg Date: 2016-08 Impact factor: 1.539
Authors: Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò Journal: Int J Mol Sci Date: 2020-11-10 Impact factor: 5.923
Authors: Kinnor Das; Steven Daveluy; George Kroumpouzos; Komal Agarwal; Indrashis Podder; Katherine Farnbach; Alex G Ortega-Loayza; Jacek C Szepietowski; Stephan Grabbe; Mohamad Goldust Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241